Article
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2020
Shattuck-Brandt Rebecca L, Chen Sheau-Chiann, Murray Emily, Johnson Christopher Andrew, Crandall Holly, O'Neal Jamye F, Al-Rohil Rami Nayef, Nebhan Caroline A, Bharti Vijaya, Dahlman Kimberly B, Ayers Gregory D, Yan Chi, Kelley Mark C, Kauffmann Rondi M, Hooks Mary, Grau Ana, Johnson Douglas B, Vilgelm Anna E, Richmond Ann
Abstract excerpt
PURPOSE: Over 60% of patients with melanoma respond to immune checkpoint inhibitor (ICI) therapy, but many subsequently progress on these therapies. Second-line targeted therapy is based on BRAF mutation status, but no available agents are available for NRAS, NF1, CDKN2A, PTEN, and TP53 mutations. Over 70% of melanoma tumors have activation of the MAPK pathway due to BRAF or NRAS mutations, while loss or mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.